A235980 Stock Overview
A drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
MedPacto, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩7,450.00 |
52 Week High | ₩17,240.00 |
52 Week Low | ₩6,110.00 |
Beta | 0.80 |
11 Month Change | -6.76% |
3 Month Change | -20.32% |
1 Year Change | -49.35% |
33 Year Change | -88.14% |
5 Year Change | n/a |
Change since IPO | -58.50% |
Recent News & Updates
Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In Growth
Aug 05MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans
Mar 28Shareholder Returns
A235980 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -10.7% | -1.2% | -2.1% |
1Y | -49.4% | 28.3% | 0.3% |
Return vs Industry: A235980 underperformed the KR Biotechs industry which returned 28.3% over the past year.
Return vs Market: A235980 underperformed the KR Market which returned 0.3% over the past year.
Price Volatility
A235980 volatility | |
---|---|
A235980 Average Weekly Movement | 6.7% |
Biotechs Industry Average Movement | 8.1% |
Market Average Movement | 5.1% |
10% most volatile stocks in KR Market | 11.2% |
10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A235980's share price has been volatile over the past 3 months.
Volatility Over Time: A235980's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 62 | Seong-Jin Kim | www.medpacto.com |
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
MedPacto, Inc. Fundamentals Summary
A235980 fundamental statistics | |
---|---|
Market cap | ₩250.18b |
Earnings (TTM) | -₩30.63b |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.2x
P/E RatioIs A235980 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A235980 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩30.63b |
Earnings | -₩30.63b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -912.20 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did A235980 perform over the long term?
See historical performance and comparison